Name: The art and Science of Physiologically-Based Pharmacokinetics Modeling (en Inglés)
Price: 135330.00 CLP
Availability: InStock
Author: Cristofoletti Rodrigo,Rostami-Hodjegan Amin
ISBN: 9780367468873

portada The art and Science of Physiologically-Based Pharmacokinetics Modeling (en Inglés)

Formato

Libro Físico

Editorial

Crc Press

Autor

Cristofoletti Rodrigo,Rostami-Hodjegan Amin

Idioma

Inglés

N° páginas

344

Encuadernación

Tapa Dura

ISBN13

9780367468873

N° edición

The art and Science of Physiologically-Based Pharmacokinetics Modeling (en Inglés)

Cristofoletti Rodrigo,Rostami-Hodjegan Amin (Autor) · Crc Press · Tapa Dura

Libro Nuevo

$ 135.330

$ 225.550

Ahorras: $ 90.220

40% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 05 de Junio y el Lunes 17 de Junio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "The art and Science of Physiologically-Based Pharmacokinetics Modeling (en Inglés)"

This state of the art text describes the science behind the system and drug-dependent components of PBPK models, its applications in translational and regulatory science e.g. guiding drug discovery and development, and supporting precision medicine initiatives. In order to incorporate the state-of-the-art knowledge, each chapter is written by leaders in the field and illustrated by clear case studies. Connecting basic and applied science, the book explores the potential of PBPK modeling for improving therapeutics and is designed for a wide audience encompassing graduate students as well as biopharmaceutics scientists and clinical pharmacologists.Features: 1. Provides a basic understanding of the physiologically based pharmacokinetic modelling and its applications2. Assists the reader in understanding product performance to allow for rapid product development and establish bioequivalence3. Well-constructed content and added value of real examples4. Illustrates how using available resources via modeling and simulation leads to a reduction in the costs related to drug development, which directly affects the costs to patients